Magna Mining announced its Q3 2026 results, highlighting a temporary geological issue at McCreedy West that reduced production and led to a downward revision of 2026 payable copper equivalent production guidance to 14.5-15.5 million pounds. Despite challenges, the mine remained profitable with a $4.9 million cash margin in Q3. The company is progressing with the restart of Levack Mine and construction of Crean Hill Project, both expected to boost future production. Magna ended Q3 with strong cash reserves of $168.4 million and plans to return to higher-grade ore production in 2027.
Magna Mining's Q3 2026 results provide context for readers, with Pluang market data as of Nov 12, 2026 04:11 WIB showing that among 83 priced Basic Materials-sector US stocks, 36 rose and 47 fell. Notable movers include LYB at USD 62.59 with a 3.28% increase and a typical hold time of 91 days, DOW at USD 32.51 up 3.27% but with 99% sell order activity, and SOLS at USD 67.13 gaining 3.25% with a 21-day typical hold time. The most notable figure is DOW's 99% sell order activity on Pluang.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
